NCT00838955 2024-07-10
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Loyola University
Phase 2 Terminated
Clinical Trials
10 trialsNCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01264341 2017-02-14
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT01061606 2016-11-09
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01009203 2015-08-10
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01079767 2014-03-04
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT00887640 2014-02-26
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Duke University
Phase 2 Terminated
NCT00086840 2013-01-24
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00926107 2011-11-10
Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse
Hellenic Cooperative Oncology Group
Phase 2 Terminated